The C1QTNF family, short for C1q and TNF related proteins, consists of a group of secreted proteins that are characterized by a C1q domain at their C-terminus, similar to that found in the complement component C1q and tumor necrosis factor (TNF). These proteins are involved in various biological processes, including inflammation, metabolism, and cell signaling. The C1QTNF family members are known to interact with a range of receptors and signaling molecules, influencing pathways related to insulin sensitivity, adipocyte function, and energy homeostasis. Functionally, C1QTNF proteins have been implicated in the regulation of glucose and lipid metabolism, and disturbances in their expression or activity are associated with metabolic disorders such as obesity, diabetes, and cardiovascular diseases.
Some members of this family are also involved in modulating immune responses, potentially influencing the development and progression of inflammatory and autoimmune diseases. The signaling pathways activated by C1QTNF proteins can involve classical receptors, such as G protein-coupled receptors, and can lead to the activation of various downstream signaling cascades, including NF-κB and MAPK pathways. Targeting C1QTNF proteins for disruption or inhibition using small molecules allows for the exploration of their role in metabolic and inflammatory pathways. By inhibiting the activity of these proteins, researchers can observe changes in metabolic processes, such as glucose and lipid metabolism, and assess the impact on related diseases like diabetes and obesity. Small molecule inhibitors can also help elucidate the role of C1QTNF proteins in immune modulation, providing insights into their involvement in inflammation and autoimmune conditions.
VOIR ÉGALEMENT...
Items 1 to 10 of 20 total
Afficher:
| Nom du produit | CAS # | Ref. Catalogue | Quantité | Prix HT | CITATIONS | Classement |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibe la MAPK p38, influençant le rôle du C1QTNF (apparenté au C1q et au TNF) dans les réponses cellulaires au stress. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
Inhibe CaMKII et peut affecter C1QTNF (C1q et TNF) dans les voies de signalisation du calcium. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
Chélateur du calcium qui peut inhiber la fonction du C1QTNF (apparenté au C1q et au TNF) dans les voies dépendantes du calcium. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibiteur de JNK qui peut avoir un impact sur le rôle du C1QTNF (lié au C1q et au TNF) dans le stress et la survie cellulaires. | ||||||
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 612847-09-3 | sc-202048 sc-202048A | 1 mg 5 mg | $204.00 $265.00 | 29 | |
Inhibe Akt, impactant la signalisation C1QTNF (C1q et TNF) dans les voies liées à la survie et à la croissance des cellules. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Inhibiteur de la génistéine kinase qui peut perturber l'interaction du C1QTNF (apparenté au C1q et au TNF) avec les enzymes nécessitant une phosphorylation. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Le ruxolitinib est un inhibiteur de JAK1 et JAK2 qui perturbe la voie JAK-STAT, entraînant la régulation à la baisse de la production de C1QTNF (C1q et TNF) et des réponses inflammatoires. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $196.00 $651.00 | ||
Le baricitinib inhibe le C1QTNF (lié au C1q et au TNF) en ciblant JAK1 et JAK2, perturbant ainsi les voies de signalisation intracellulaires impliquées dans l'inflammation et la libération de cytokines. | ||||||
Ibuprofen | 15687-27-1 | sc-200534 sc-200534A | 1 g 5 g | $52.00 $86.00 | 6 | |
L'ibuprofène réduit les niveaux de C1QTNF (C1q et TNF) en inhibant les enzymes COX, qui sont responsables de la conversion de l'acide arachidonique en prostaglandines inflammatoires. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Le méthotrexate inhibe la dihydrofolate réductase (DHFR), ce qui entraîne la suppression de la synthèse de l'ADN et de la production de C1QTNF (apparenté au C1q et au TNF) dans les cellules impliquées dans la réponse immunitaire. | ||||||